The State of Biosimilars in the United States: Center for Biosimilars Peer Exchange
b'The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. In the following Peer Exchange discussion from the Center for Biosimilars, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars.\\n\\nThe Center for Biosimilars, a sister site of The American Journal of Managed Care, serves as an online resource that brings together the worlds of clinical, business, regulatory, policy, and economic outcomes of biosimilars.\\n\\nFor more insight into the world of biosimilar therapies, visit centerforbiosimilars.com.'